Supplementary Table S1 Definition of outcomes.

Study	Definitions
Aoki 2005	All-cause death: Deaths from all causes were reported.
	Myocardial infarction: In the first 7 days after the intervention, a definite diagnosis of myocardial infarction was made if there
	was documentation of new abnormal Q waves and either cardiac enzymes greater than five times the upper limit of normal or a
	ratio of peak serum creatinine kinase-myocardial band to creatinine kinase greater than 0.1. From the eighth day onwards, either
	abnormal Q waves or enzymatic changes were sufficient for a diagnosis of myocardial infarction.
Chang 2012	Not reported.
Chang 2013	All-cause death: Death from any cause.
	Acute coronary syndrome: Either acute myocardial infarction or unstable angina.
	Repeat revascularization: Coronary artery bypass grafting procedures occurring within 14 days of the initial revascularization
	and percutaneous coronary interventions occurring within 3 days of the initial revascularization were considered part of the
	index procedure and not as repeat revascularizations.
Bangalore 2015	Myocardial infarction: Myocardial infarction included both procedural myocardial infarction (defined as new Q waves in both
	the Percutaneous Coronary Intervention Reporting System and the Cardiac Surgery Reporting System) and spontaneous
	myocardial infarction (defined as an emergency admission with a principal diagnosis of myocardial infarction or a principal
	diagnosis of cardiogenic shock with a secondary diagnosis of myocardial infarction).
	Stroke: Stroke was identified either as a complication at the time of the index procedure or at readmission (principal diagnosis
	of stroke).
	Repeat revascularization: Repeat revascularization was identified as any unstaged revascularization after the index procedure.

	Staged revascularization was defined as a nontarget vessel revascularization within 90 days of the index procedure that was
	coded as intended to be staged in the index procedure and at the time of the staged procedure.
Chan 2015	Not reported.
Komiya 2015	All-cause death: Death from any cause. Death was regarded as cardiac in origin unless obvious non-cardiac causes could be
	identified.
	Myocardial infarction: In the first 7 days after the intervention, a definite diagnosis of myocardial infarction was made if there
	was documentation of new abnormal Q waves and either cardiac enzymes greater than five times the upper limit of normal or a
	ratio of peak serum creatinine kinase-myocardial band to creatinine kinase greater than 0.1. From the eighth day onwards, either
	abnormal Q waves or enzymatic changes were sufficient for a diagnosis of myocardial infarction.
	Stroke: Stroke was defined as an ischemic or hemorrhagic stroke with symptoms lasting more than 24 h either during the index
	hospitalization for the initial coronary revascularization or requiring hospitalization during follow-up.
	Repeat revascularization: Any revascularization performed after 3 months of the initial procedure.
Baber 2016	Myocardial infarction: Spontaneous myocardial infarction was defined as a typical increase in the troponin level or a more
	rapid rise and fall in the myocardial band fraction of creatine kinase with the presence of one or more of the following factors:
	ischemic symptoms, development of pathologic Q waves on electrocardiography, changes indicative of ischemia on
	electrocardiography, the need for repeated coronary artery intervention, or pathologic findings of an acute myocardial infarction.
	Periprocedural myocardial infarction was defined as the presence of new Q waves in at least 2 or more contiguous leads when
	compared to baseline within 30 days of any revascularization procedure. Analyses for the outcome of myocardial infarction were
	repeated after excluding periprocedural events.
	Stroke: A focal neurological deficit of central origin lasting more than 72 hours; or A focal neurological deficit of central origin

	lasting more than 24 hours with imaging evidence of cerebral infarction or intracerebral hemorrhage; or A non-focal
	encephalopathy lasting more than 24 hours with imaging evidence of cerebral infarction or hemorrhage adequate to account for
	the clinical state.
Giustino 2018	All-cause death: Death from any cause. The cause of death will be adjudicated as being due to cardiovascular causes, non-
	cardiovascular causes, or undetermined causes.
	Myocardial infarction: Myocardial infarction included both post-procedure myocardial infarction and spontaneous myocardial
	infarction. Post-procedure myocardial infarction: Defined as the occurrence within 72 hours after either percutaneous
	coronary intervention or coronary artery bypass grafting of either: creatinine kinase-myocardial band >10x upper reference limit,
	or creatinine kinase-myocardial band >5x upper reference limit, plus new pathological Q waves in at least 2 contiguous leads or
	new persistent non-rate related left bundle branch block, or angiographically documented graft or native coronary artery
	occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow, or imaging evidence of new loss of viable
	myocardium or new regional wall motion abnormality. Spontaneous myocardial infarction: Defined as the occurrence >72
	hours after any percutaneous coronary intervention or coronary artery bypass grafting of: The rise and/or fall of cardiac
	biomarkers (creatinine kinase-myocardial band or troponin) >1x upper reference limit, plus: electrocardiogram changes
	indicative of new ischemia [ST-segment elevation or depression, in the absence of other causes of ST-segment changes such as
	left ventricular hypertrophy or bundle branch block], or development of pathological Q waves (≥0.04 seconds in duration and
	≥1 mm in depth) in ≥2 contiguous precordial leads or ≥2 adjacent limb leads) of the electrocardiogram, or angiographically
	documented graft or native coronary artery occlusion or new severe stenosis with thrombosis and/or diminished epicardial flow,
	or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
	Stroke: Strokes will be classified as ischemic, hemorrhagic, or unknown. Four criteria must be fulfilled to diagnosis stroke:

	1. Rapid onset of a focal/global neurological deficit with at least one of the following: change in level of consciousness,				
	hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia/aphasia, hemianopia, amaurosis				
	fugax, other new neurological sign(s)/symptom(s) consistent with stroke; and				
	2. Duration of a focal/global neurological deficit ≥24 hours or <24 hours if any of the following conditions exist: i. At least				
	one of the following therapeutic interventions: a. Pharmacologic (i.e., thrombolytic drug administration) b. Non-pharmacologic				
	(i.e., neurointerventional procedure such as intracranial angioplasty) ii. Available brain imaging clearly documents a new				
	hemorrhage or infarct iii. The neurological deficit results in death				
	3. No other readily identifiable non-stroke cause for the clinical presentation (e.g., brain tumor, trauma, infection,				
	hypoglycemia, other metabolic abnormality, peripheral lesion, or drug side effect). Patients with non-focal global				
	encephalopathy will not be reported as a stroke without unequivocal evidence based upon neuroimaging studies.				
	4. Confirmation of the diagnosis by a neurology or neurosurgical specialist and at least one of the following: a. Brain imaging				
	procedure (at least one of the following): i. computerized tomography scan ii. magnetic resonance imaging scan iii. Cerebral				
	vessel angiography b. Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial hemorrhage).				
	All strokes with stroke disability of modified Rankin Scale ≥1 (increase from baseline assessment) will be included in the				
	primary endpoint. All diagnosed strokes (even with modified Rankin Scale 0) will also be tabulated.				
	Ischemia-driven revascularization: A coronary revascularization procedure may be either a coronary artery bypass grafting or				
	a percutaneous coronary intervention.				
Lima 2018	Myocardial infarction: Myocardial infarction was blindly adjudicated and defined as the presence of significant new Q waves				
	in at least two electrocardiographic leads or symptoms compatible with myocardial infarction associated with creatine kinase-				
	myocardial band fraction concentrations that were more than three times the upper limit of the reference range.				

Milojevic 2018	All-cause death: Death from any cause. Deaths were considered cardiac unless an unequivocal, noncardiac cause was
	established.
	Myocardial infarction: Myocardial infarction was defined in relation to intervention status as follows: i) after allocation but
	before treatment: Q-wave (new pathological Q-waves in ≥2 leads lasting ≥0.04 seconds with creatine kinase-myocardial band
	levels elevated above normal), and non-Q wave myocardial infarction (elevation of creatine kinase levels >2 times the upper
	limit of normal with positive creatine kinase-myocardial band or elevation of creatine kinase levels to >2 times the upper limit
	of normal without new Q-waves if no baseline creatine kinase-myocardial band was available); ii) <7d after intervention: new
	Q-waves and either peak creatine kinase-myocardial band /total creatine kinase >10% or plasma level of creatine kinase-
	myocardial band 5x the upper limit of normal; iii) ≥7d after intervention: new Q waves or peak creatine kinase-myocardial band
	/total creatine kinase >10% or plasma level of creatine kinase-myocardial band 5x the upper limit of normal or plasma level of
	creatine kinase 5x the upper limit of normal.
	Stroke: Stroke was defined as a focal, central neurological deficit lasting >72 hours which resulted in irreversible brain damage
	or body impairment.
	Repeat revascularization: Repeat revascularization was defined as any repeat percutaneous coronary intervention or coronary
	artery bypass grafting.
Gaipov 2019	Not reported.

Supplementary Table S2 Quality assessment of observational studies using the Newcastle–Ottawa scale.

Study	Selection	Comparability	Outcome	Total Score
Chang 2012	4	2	3	9
Chang 2013	4	2	3	9
Bangalore 2015	4	2	3	9
Chan 2015	4	2	3	9
Komiya 2015	4	2	3	9
Gaipov 2019	4	2	3	9

Supplementary Table S3 Quality assessment of randomized controlled trials.

Study	Sequence	Concealment of	Blinding of participants,	Incomplete	Free of	Free of
	generation	allocation	personnel and outcome	outcome data	selective	other bias
			assessors	addressed	reporting	
Aoki 2005	Low	Low	Moderate	Low	Low	Low
Baber 2016	Low	Low	Moderate	Low	Low	Low
Giustino 2018	Low	Low	Moderate	Low	Low	Low
Lima 2018	Low	Low	Moderate	Low	Low	Low
Milojevic 2018	Low	Low	Moderate	Low	Low	Low

Supplementary Table S4 Publication bias.

Outcomes	p Egger test	p Begg test
Long-term all-cause death	0.196	1.000
Short-term death	0.505	0.734
Myocardial infarction	0.839	0.754
Stroke	0.113	0.133
Repeat revascularization	0.237	0.902


Supplementary Table S5 Meta-regression analysis.

Outcome	Patient characteristics	Regression coefficient (95% CI)	P value
Long-term death	Age	-0.021 (-0.071 to 0.028)	0.346
	Gender	0.002 (-0.033 to 0.036)	0.912
	Diabetes	-0.0004 (-0.010 to 0.010)	0.928
	Hypertension	-0.015 (-0.037 to 0.006)	0.137
	Dyslipidemia	-0.003 (-0.011 to 0.006)	0.456
	Prior myocardial infarction	-0.004 (-0.034 to 0.025)	0.723
Short-term death	Age	-0.119 (-0.186 to 0.424)	0.235
	Gender	0.0004 (-0.301 to 0.302)	0.996
	Diabetes	-0.107 (-0.324 to 0.110)	0.168
	Hypertension	0.105 (-0.121 to 0.331)	0.184
	Dyslipidemia	0.057 (-0.062 to 0.176)	0.176
	Prior myocardial infarction	0.153 (-1.004 to 1.310)	0.342
Myocardial infarction	Age	-0.070 (-0.333 to 0.194)	0.542
	Gender	0.046 (-0.055 to 0.148)	0.306
	Diabetes	-0.011 (-0.037 to 0.014)	0.309
	Hypertension	-0.030 (-0.077 to 0.017)	0.168
	Dyslipidemia	-0.031 (-0.071 to 0.008)	0.103
	Prior myocardial infarction	-0.045 (-0.089 to -0.001)	0.047
Stroke	Age	-0.087 (-0.232 to 0.058)	0.184
	Gender	-0.010 (-0.107 to 0.087)	0.803

	Diabetes	0.012 (-0.008 to 0.033)	0.187
	Hypertension	0.022 (-0.022 to 0.065)	0.256
	Dyslipidemia	0.002 (-0.040 to 0.045)	0.899
	Prior myocardial infarction	-0.045 (-0.187 to 0.098)	0.393
Repeat	Age	-0.180 (-0.420 to 0.060)	0.116
revascularization	Gender	0.078 (-0.022 to 0.179)	0.106
	Diabetes	-0.0004 (-0.028 to 0.027)	0.972
	Hypertension	-0.003 (-0.054 to 0.047)	0.880
	Dyslipidemia	-0.001 (-0.050 to 0.048)	0.957
	Prior myocardial infarction	-0.042 (-0.068 to -0.016)	0.011


CI, confidence interval.

Supplementary Figure S1 Sensitivity analysis. CI, confidence interval.




Supplementary Figure S2 Publication bias. OR, odds ratio.


A. Long-term all-cause mortality




B. Short-term mortality



C. Myocardial infarction



D. Stroke



E. Repeat revascularization

